16/04/2018 16:36:00

Boston Therapeutics to Hold Business Update Conference Call Wednesday, April 18, 2018 at 5:00 p.m. ET

LAWRENCE, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (the “Company” or “BTI”) (OTCQB:BTHE), an innovator in the design, development and commercialization of novel therapeutics for the potential treatment of diabetes and related complications, will hold a conference call on Wednesday, April 18, 2018 at 5:00 p.m. Eastern time (2:00 p.m. Pacific time) to discuss recent business developments, including its recent acquisition of CureDM and recently announced intention to acquire Medical Technology Associates II, Inc. Boston Therapeutics management will host the presentation, followed by a question and answer period.

Date: Wednesday, April 18, 2018

Time: 5:00 p.m. Eastern time (2:00 p.m. Pacific time)

U.S. dial-in: 1-800-263-0877

TOLL/INTERNATIONAL dial-in:  1-323-794-2094

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact ViaVid at toll-free (888) 562-0262 | tel (604) 929-1352.

The conference call will be broadcast live and available for replay at the Investor Relations section of Boston Therapeutics website. A replay of the conference call will be available after 8:00 p.m. Eastern time on the same day through May 02, 2018.

Toll-free replay number: 1-844-512-2921

International replay number: 1-412-317-6671

Replay ID: 2971422

Investor Relations Contact:  Loraine V. Upham

About Boston Therapeutics, Inc. 

www.bostonti.com

 

Boston Therapeutics, headquartered in Lawrence, MA (OTCQB:BTHE) and with an office in Albuquerque, NM is an innovator in design, development and commercialization of novel compounds to treat diabetes and diabetes related complications.  The company has proprietary compounds based on glucose chemistry, peptide chemistry and protein conjugates. 

Contact: Boston Therapeutics, Inc.

Loraine Upham, COO 

Phone: 603-935-9799

Email: loraine.upham@bostonti.com 

www.bostonti.com

 

 

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
14 Apr
BAVA
Som det nok er mange bekendt, er kursen på Bavarians aktie faldet meget betydeligt, ca. 30%, over de..
31
15 Apr
OMXC25
Virkelig intelligent indlæg. En masse om at markedet er på vej til nedtur, men sjovt nok ikke så meg..
24
19 Apr
 
Et opgør med Finanstilsynet er tvingende nødvendigt, hvis tilliden til markedet ikke skal lægges øde..
22
18 Apr
 
LÆS NU FOR HELVEDE NOGEN AF DE 38000 indlæg som siger at børsen er nede!   Det er kraftstejleme da u..
21
14 Apr
OMXC25
Følgende er oplæg til debat, om aktiernes udviklign de kommende måneder ud fra handelskrig og naturl..
17
19 Apr
BAVA
      Vedr. shortsqeeze mm. og den ekstreme kursmanipulation der dagligt foregår på Nasdaq Kbhvn. T..
16
18 Apr
 
Det er en katastrofe ! Hvis det fortsætter ret meget længere er vi allesammen nødt til at gå ud og l..
16
13 Apr
BAVA
DER ER ET KÆMPE PROBLEM... med alle de indlæg som kommer på Bavarian iøjeblikket...  Der kommer INTE..
15
17 Apr
LAUR
An aktie man aldrig skal eje. Ejerne trækker store summer ud, at en virksomhed der kæmper for overle..
14
19 Apr
 
Hej alle,   Jeg lavede et lille indlæg på Stolt-Nielsen for nylig hvor jeg desværre – og det beklage..
13

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer
2
Leading Petroleum Industry Engineer and Researcher Joins Stamper Oil and Gas Technical Advisory Board
3
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
4
Brookfield Residential’s Stunning New Agave Neighborhood to Debut Soon at Spencer’s Crossing in Murrieta
5
Urban Airship Names Michael Stone as Senior Vice President of Marketing

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
20 April 2018 05:32:23
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: ReleaseBuild_20180417.1 - EUROWEB1 - 2018-04-20 06:32:23 - 2018-04-20 05:32:23 - 1000 - Website: OKAY